Today: 28 February 2026
Subscribe
Browse Category

NYSE:NVO 12 November 2025 - 23 December 2025

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

U.S. regulators approved Novo Nordisk’s once-daily oral Wegovy pill for chronic weight management and cardiovascular risk reduction on Dec. 23, 2025. Novo shares rose about 9% in U.S. trading, with investors reacting to the company’s first-to-market status for a high-efficacy oral GLP-1 obesity drug. The FDA decision also lifted European healthcare stocks, pushing the STOXX 600 to a record high.
23 December 2025
·
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly shares traded near $1,076 after the FDA approved Novo Nordisk’s first daily oral Wegovy for obesity. Novo plans a U.S. launch in January 2026, beating Lilly’s own oral candidate, which remains under review. Novo shares rose on the news; Lilly slipped slightly. Analysts expect oral obesity drugs could reach 20% of the market by 2030.
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management in the U.S., marking the first oral GLP-1 agonist cleared for this use. Shares jumped on the news, lifting European healthcare stocks. The company reported 16.6% mean weight loss in trials when taken as prescribed. Novo plans to launch the pill in the U.S. in early January 2026.
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly shares closed up 0.47% at $1,076.48 Monday, then fell about 1% in after-hours trading after the FDA approved Novo Nordisk’s Wegovy weight-loss pill. Novo’s U.S. shares jumped roughly 6% following the news. The new oral semaglutide is the first FDA-cleared pill for obesity, with Novo saying it will launch early next year at $149 a month. Lilly’s own oral obesity drug, orforglipron, could be approved as soon as late March.
23 December 2025
····
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly shares closed up 1.45% at $1,056.88 Thursday after reporting positive Phase 3 results for its oral obesity drug orforglipron. Patients switching from injectable GLP-1 drugs maintained weight loss, with those from Wegovy averaging 0.9 kg change and those from Zepbound 5 kg. The stock held steady in after-hours trading. Detailed trial data will be released later.
18 December 2025
···
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk shares have dropped about 45% in 2025 and over 50% from their 2024 peak, following profit warnings, slower GLP-1 growth, and a failed Alzheimer’s trial. The stock now trades near $47.9, down sharply after the EVOKE and EVOKE+ studies showed no significant benefit for semaglutide in early Alzheimer’s. Revenue in Q3 2025 rose 5% to DKK 74.98 billion, missing analyst expectations.
7 December 2025
··
Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk ADRs traded near $49.25 Friday, up about 1%, with volume topping 6.7 million shares. Goldman Sachs cut its 12-month price target to $54 from $60 but kept a “Buy” rating, implying about 10% upside. Novo’s Copenhagen shares remain down nearly 49% year to date. Analyst targets have drifted lower, with consensus now around $54–57 per ADR.
28 November 2025
·
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk shares rebounded sharply on 26 November, with U.S. ADRs up 3.7% to $48.79 and Copenhagen shares closing 4.7% higher at DKK 314.20. The rally followed an FDA filing for a higher-dose Wegovy, Medicare pricing clarity, and renewed interest in the company’s next-generation obesity drug. Despite the gains, Copenhagen shares remain down nearly 50% year-to-date.
26 November 2025
···
NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Novo Nordisk ADRs rose 4.7% to $47.08 in late trading Tuesday after mid-stage trial data showed its experimental obesity drug amycretin led to up to 14.5% weight loss in type 2 diabetes patients. The rebound follows a 5% drop Monday on failed Alzheimer’s trials. NVO remains down over 50% in the past year and trades near 52-week lows amid guidance cuts and competition from Eli Lilly.
25 November 2025
··
US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

U.S. stock futures rose Monday, with Dow, S&P 500, and Nasdaq up 0.3% to 1% pre-market as traders bet on a possible December Fed rate cut. Bitcoin rebounded above $85,000, boosting crypto stocks. Novo Nordisk shares fell sharply after its Alzheimer’s trial failed. No major U.S. economic data is due today due to a government shutdown delay.
25 November 2025
···
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk’s U.S. shares fell 1.1% to $47.07 by late morning, while Copenhagen B-shares closed down nearly 3% at DKK 305, extending a year-to-date drop of about 45%. Denmark compensated four patients for vision loss linked to Wegovy and Ozempic. Novo Nordisk and Eli Lilly launched direct-to-employer GLP-1 drug programs, and Novo cut self-pay prices for its weight-loss drugs.
21 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk’s U.S. ADR traded near $49 Thursday, steady after a 3% rebound, while Copenhagen shares rose about 2–2.5% to DKK 318–319. The company faces slowing GLP-1 demand, price cuts, and high-profile Alzheimer’s trials, with results expected December 3. Shares remain down over 10% in three months and nearly 46% year-to-date after guidance cuts.
20 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Novo Nordisk cut U.S. self-pay prices for Wegovy and Ozempic and launched a $199 two-month introductory offer for new patients. Shares fell 1.9% to $47.55 intraday as investors weighed pricing pressure and governance changes. Novo Holdings exited its 7.8% stake in ConvaTec in London. Trading volumes reached about 7.9 million shares by 16:12 UTC.
18 November 2025
··
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD announced $199 monthly cash-pay pricing for starter doses of Wegovy and Ozempic, available to new patients for their first two fills through its Weight Management Program. The move follows a partnership with Novo Nordisk and comes hours before LifeMD’s delayed Q3 2025 earnings release, rescheduled for Nov. 17. LFMD shares traded around $4.60 this afternoon, slightly down despite the news.
17 November 2025
··
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio shares plunged nearly 80% to around $6.60 in pre-market trading Thursday after the company reported mixed early data from its lead RNA-editing program, KRRO‑110, and announced layoffs, a pipeline shift, and a year-long pause in its Novo Nordisk partnership. The Phase 1/2a trial showed KRRO‑110 increased AAT protein but did not reach protective levels.
13 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
1 2 3 4 5 6 7
Go toTop